[Dilip Davda] For the last three fiscals, Nidan Laboratories top line remained static, but profit margins improved with a sharp rise for FY21. It has expressed similar trends for FY22 Q1, but the sustainability of such margins going forward is a major concern as the segment is highly fragmented and witnessing a cutthroat competition. Due to pandemics, these segments gained fancy and perhaps this company is trying to encase on this boom. Based on financial parameters the asking price is high. Hence there is no harm in ignoring this issue. Read detail review...

Nidan Laboratories IPO Review by Members

Nidan Laboratories IPO Reviews, analysis and views by popular members. Read Nidan Laboratories & Healthcare Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Nidan Laboratories IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Nidan Laboratories IPO Review & Recommendations

Nidan Laboratories IPO Review Summary from brokers and analysts

Nidan Laboratories IPO Review by Dilip Davda (Avoid)

Nidan Laboratories IPO Review by Members

Nidan Laboratories IPO Review Summary by Members

Read more about Nidan Laboratories IPO